Severe Community-Acquired Pneumonia (CAP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Severe Community-Acquired Pneumonia (CAP) Market Outlook

Thelansis’s “Severe Community-Acquired Pneumonia (CAP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Severe Community-Acquired Pneumonia (CAP) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Severe Community-Acquired Pneumonia (CAP) Overview

Severe Community-acquired pneumonia (CAP) is a leading cause of hospitalisation and mortality and incurs high healthcare costs. Because disease presentation varies from a mild illness that can be managed as an outpatient to a severe illness that requires treatment in the intensive care unit (ICU), determining the appropriate level of care, in addition to early diagnosis and appropriate and timely treatment, is essential for improving outcomes. Most patients with Severe Community-acquired pneumonia have chronic underlying diseases like COPD in one-third of the population. The cases of community-acquired pneumonia requiring hospitalisation were highest among the oldest adults. Despite current diagnostic tests, no pathogen was detected in most patients. Respiratory viruses were detected more frequently than bacteria. Community-acquired pneumonia (CAP) is considered the most infectious cause of sepsis globally, and approximately 50% of intensive care unit (ICU) admissions due to CAP are associated with septic shock. Because many microorganisms, including fungi, viruses, and bacteria, can cause community-acquired pneumonia, it is essential to identify the pathogenic microorganism that causes the infection in order to provide an adequate clinical diagnosis. Streptococcus pneumonia is the most common pathogen responsible for CAP; ~50% of patients with CAP still have unidentified organisms.

• The incidence of Community-acquired pneumonia ranges from 345 to 650 cases per 100,000 population in the USA.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: